JPWO2019217890A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019217890A5 JPWO2019217890A5 JP2020563698A JP2020563698A JPWO2019217890A5 JP WO2019217890 A5 JPWO2019217890 A5 JP WO2019217890A5 JP 2020563698 A JP2020563698 A JP 2020563698A JP 2020563698 A JP2020563698 A JP 2020563698A JP WO2019217890 A5 JPWO2019217890 A5 JP WO2019217890A5
- Authority
- JP
- Japan
- Prior art keywords
- cycloalkyl
- alkyl
- hydrogen
- linear
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 1391
- 229910052739 hydrogen Inorganic materials 0.000 claims description 604
- 239000001257 hydrogen Substances 0.000 claims description 580
- 150000002431 hydrogen Chemical class 0.000 claims description 418
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 384
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 306
- 150000001875 compounds Chemical class 0.000 claims description 183
- 125000003545 alkoxy group Chemical group 0.000 claims description 171
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 162
- 125000001188 haloalkyl group Chemical group 0.000 claims description 153
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 140
- -1 diastereomers Chemical class 0.000 claims description 126
- 150000003839 salts Chemical class 0.000 claims description 123
- 239000012453 solvate Substances 0.000 claims description 88
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 76
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 74
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 74
- 229910052736 halogen Inorganic materials 0.000 claims description 74
- 150000002367 halogens Chemical class 0.000 claims description 74
- 229910052799 carbon Inorganic materials 0.000 claims description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 125000004429 atom Chemical group 0.000 claims description 15
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 12
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 125000006413 ring segment Chemical group 0.000 claims description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 102100039126 5-hydroxytryptamine receptor 7 Human genes 0.000 claims description 6
- 101710150237 5-hydroxytryptamine receptor 7 Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 4
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 4
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 4
- 208000004232 Enteritis Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
- 230000008482 dysregulation Effects 0.000 claims description 4
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000017164 Chronobiology disease Diseases 0.000 claims description 2
- 206010058314 Dysplasia Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000027534 Emotional disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000020358 Learning disease Diseases 0.000 claims description 2
- 208000004852 Lung Injury Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 2
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- 208000029061 Temperature regulation disease Diseases 0.000 claims description 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 claims description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 claims description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 206010013663 drug dependence Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 230000000971 hippocampal effect Effects 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 208000013403 hyperactivity Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 201000003723 learning disability Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 231100000515 lung injury Toxicity 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 2
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 230000001314 paroxysmal effect Effects 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 208000022821 personality disease Diseases 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 230000002028 premature Effects 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 230000001932 seasonal effect Effects 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 17
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- 125000003944 tolyl group Chemical group 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024011236A JP7629123B2 (ja) | 2018-05-11 | 2024-01-29 | ５－ヒドロキシトリプタミン受容体７の調節物質としての新規官能化ラクタムおよびその使用方法 |
| JP2025013946A JP2025061975A (ja) | 2018-05-11 | 2025-01-30 | ５－ヒドロキシトリプタミン受容体７の調節物質としての新規官能化ラクタムおよびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670116P | 2018-05-11 | 2018-05-11 | |
| US62/670,116 | 2018-05-11 | ||
| PCT/US2019/031824 WO2019217890A1 (en) | 2018-05-11 | 2019-05-10 | Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024011236A Division JP7629123B2 (ja) | 2018-05-11 | 2024-01-29 | ５－ヒドロキシトリプタミン受容体７の調節物質としての新規官能化ラクタムおよびその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021523179A JP2021523179A (ja) | 2021-09-02 |
| JPWO2019217890A5 true JPWO2019217890A5 (https=) | 2022-05-17 |
| JP2021523179A5 JP2021523179A5 (https=) | 2022-05-17 |
| JP7429652B2 JP7429652B2 (ja) | 2024-02-08 |
Family
ID=66655471
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020563698A Active JP7429652B2 (ja) | 2018-05-11 | 2019-05-10 | ５－ヒドロキシトリプタミン受容体７の調節物質としての新規官能化ラクタムおよびその使用方法 |
| JP2024011236A Active JP7629123B2 (ja) | 2018-05-11 | 2024-01-29 | ５－ヒドロキシトリプタミン受容体７の調節物質としての新規官能化ラクタムおよびその使用方法 |
| JP2025013946A Pending JP2025061975A (ja) | 2018-05-11 | 2025-01-30 | ５－ヒドロキシトリプタミン受容体７の調節物質としての新規官能化ラクタムおよびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024011236A Active JP7629123B2 (ja) | 2018-05-11 | 2024-01-29 | ５－ヒドロキシトリプタミン受容体７の調節物質としての新規官能化ラクタムおよびその使用方法 |
| JP2025013946A Pending JP2025061975A (ja) | 2018-05-11 | 2025-01-30 | ５－ヒドロキシトリプタミン受容体７の調節物質としての新規官能化ラクタムおよびその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US12559494B2 (https=) |
| EP (1) | EP3790859A1 (https=) |
| JP (3) | JP7429652B2 (https=) |
| KR (1) | KR20210020182A (https=) |
| CN (2) | CN112437768B (https=) |
| AU (2) | AU2019267846B2 (https=) |
| BR (1) | BR112020023072A2 (https=) |
| CA (1) | CA3110799A1 (https=) |
| EA (1) | EA202092328A1 (https=) |
| IL (3) | IL317778A (https=) |
| MA (1) | MA52567A (https=) |
| MX (2) | MX2020012030A (https=) |
| TW (2) | TW202523659A (https=) |
| WO (1) | WO2019217890A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970223B1 (en) | 2013-03-11 | 2020-04-15 | Temple University Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| US10544117B2 (en) | 2014-09-10 | 2020-01-28 | Temple University—Of the Commonwealth System of Higher Education | 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| AU2017361078B2 (en) | 2016-11-15 | 2022-01-06 | Praeventix, Llc | Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use |
| MA49019A (fr) | 2017-03-21 | 2020-02-05 | Univ Temple | Nouveaux modulateurs du récepteur sigma 2 et leur procédé d'utilisation |
| MA49017A (fr) | 2017-03-21 | 2020-02-05 | Univ Temple | Modulateurs du récepteur 7 de la 5-hydroxytryptamine et utilisation de ces derniers en tant qu'agents thérapeutiques |
| EA202092328A1 (ru) | 2018-05-11 | 2021-04-08 | Темпл Юниверсити-Оф Зэ Коммонвелс Систем Оф Хаер Эдьюкейшн | Новые функционализированные лактамы в качестве модуляторов 5-гидрокситриптаминового рецептора 7 и способ их применения |
| GB201809295D0 (en) * | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| JP7730811B2 (ja) * | 2019-11-13 | 2025-08-28 | テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | ５－ヒドロキシトリプタミン受容体７の調節因子としての新規官能化ラクタムおよびその使用方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2647785B1 (fr) * | 1989-05-31 | 1991-09-06 | Adir | Nouveaux derives de la pyrrolidone, leur procede de preparation et les compositions pharmaceutiques les renfermant |
| DE4127404A1 (de) * | 1991-08-19 | 1993-02-25 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| GB9912701D0 (en) * | 1999-06-01 | 1999-08-04 | Smithkline Beecham Plc | Novel compounds |
| CA2440803A1 (en) * | 2001-03-07 | 2002-09-12 | Pfizer Products Inc. | Modulators of chemokine receptor activity |
| JP4203235B2 (ja) | 2001-07-05 | 2008-12-24 | 日本板硝子株式会社 | ガラスパネル |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| MXPA05008137A (es) | 2003-01-31 | 2005-09-30 | Pfizer Prod Inc | Antagonistas y agonistas de 5ht7. |
| JP2006025227A (ja) | 2004-07-08 | 2006-01-26 | Sony Corp | 情報処理装置、情報処理方法、およびプログラム、並びに記録媒体 |
| EP1875899A1 (en) | 2006-06-29 | 2008-01-09 | Laboratorios Del Dr. Esteve, S.A. | Use of 5HT7 receptor agonists for the treatment of pain |
| CA2699674C (en) | 2007-10-12 | 2013-07-16 | Eli Lilly And Company | 5-ht7 receptor antagonists |
| EP2341912B1 (en) | 2008-09-05 | 2014-01-22 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (adhd) |
| WO2010069390A1 (en) | 2008-12-19 | 2010-06-24 | Nokia Siemens Networks Oy | Method and device for data processing in an udwdm network and communication system comprising such device |
| GB201002563D0 (en) | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
| US20130287705A1 (en) | 2010-11-03 | 2013-10-31 | Mcmaster University | Method of treating mucosal inflammation |
| CN103570722A (zh) | 2012-07-19 | 2014-02-12 | 中国科学院上海药物研究所 | 稠环哒嗪酮类化合物及其制备方法和用途 |
| WO2014085413A1 (en) | 2012-11-28 | 2014-06-05 | Temple University - Of The Commonwealth System Of Higher Education | Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2b activity modulators |
| EP2970223B1 (en) * | 2013-03-11 | 2020-04-15 | Temple University Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| US10544117B2 (en) | 2014-09-10 | 2020-01-28 | Temple University—Of the Commonwealth System of Higher Education | 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| US20180221365A1 (en) | 2015-05-12 | 2018-08-09 | Temple University-Of The Commonwealth System Of Higher Education | Novel sigma-2 receptor binders and their method of use |
| AU2017361078B2 (en) | 2016-11-15 | 2022-01-06 | Praeventix, Llc | Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use |
| MA49019A (fr) * | 2017-03-21 | 2020-02-05 | Univ Temple | Nouveaux modulateurs du récepteur sigma 2 et leur procédé d'utilisation |
| MA49017A (fr) * | 2017-03-21 | 2020-02-05 | Univ Temple | Modulateurs du récepteur 7 de la 5-hydroxytryptamine et utilisation de ces derniers en tant qu'agents thérapeutiques |
| EA202092328A1 (ru) | 2018-05-11 | 2021-04-08 | Темпл Юниверсити-Оф Зэ Коммонвелс Систем Оф Хаер Эдьюкейшн | Новые функционализированные лактамы в качестве модуляторов 5-гидрокситриптаминового рецептора 7 и способ их применения |
| CN110272425B (zh) | 2018-07-02 | 2022-11-04 | 广东东阳光药业有限公司 | 吡啶酰基八氢吡咯并[3,4-c]吡咯衍生物及其用途 |
| WO2021097117A2 (en) | 2019-11-13 | 2021-05-20 | Temple University-Of The Commonwealth System Of Higher Education | Novel functionalized lactones as modulators of the 5-hydroxytryptamine receptor 7 and their method of use |
| JP7730811B2 (ja) | 2019-11-13 | 2025-08-28 | テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | ５－ヒドロキシトリプタミン受容体７の調節因子としての新規官能化ラクタムおよびその使用方法 |
-
2019
- 2019-05-10 EA EA202092328A patent/EA202092328A1/ru unknown
- 2019-05-10 AU AU2019267846A patent/AU2019267846B2/en active Active
- 2019-05-10 MA MA052567A patent/MA52567A/fr unknown
- 2019-05-10 KR KR1020207035307A patent/KR20210020182A/ko not_active Ceased
- 2019-05-10 US US17/054,468 patent/US12559494B2/en active Active
- 2019-05-10 WO PCT/US2019/031824 patent/WO2019217890A1/en not_active Ceased
- 2019-05-10 EP EP19726837.8A patent/EP3790859A1/en active Pending
- 2019-05-10 MX MX2020012030A patent/MX2020012030A/es unknown
- 2019-05-10 CA CA3110799A patent/CA3110799A1/en active Pending
- 2019-05-10 TW TW113132100A patent/TW202523659A/zh unknown
- 2019-05-10 IL IL317778A patent/IL317778A/en unknown
- 2019-05-10 TW TW108116303A patent/TWI856012B/zh active
- 2019-05-10 CN CN201980046137.1A patent/CN112437768B/zh active Active
- 2019-05-10 CN CN202510743117.7A patent/CN120365202A/zh active Pending
- 2019-05-10 BR BR112020023072-3A patent/BR112020023072A2/pt unknown
- 2019-05-10 IL IL324877A patent/IL324877A/en unknown
- 2019-05-10 JP JP2020563698A patent/JP7429652B2/ja active Active
-
2020
- 2020-11-05 IL IL278523A patent/IL278523B1/en unknown
- 2020-11-10 MX MX2024008100A patent/MX2024008100A/es unknown
-
2024
- 2024-01-29 JP JP2024011236A patent/JP7629123B2/ja active Active
- 2024-12-10 AU AU2024278241A patent/AU2024278241A1/en active Pending
-
2025
- 2025-01-30 JP JP2025013946A patent/JP2025061975A/ja active Pending
- 2025-11-14 US US19/390,312 patent/US20260070908A1/en active Pending
- 2025-11-14 US US19/390,298 patent/US20260070907A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523179A5 (https=) | ||
| JP2024050527A5 (https=) | ||
| TWI765451B (zh) | 作為erk抑制劑的螺環類化合物及其應用 | |
| JP3043411B2 (ja) | タクサン誘導体の製造法、製造される新規な誘導体、及びこれを含む製薬学的組成物 | |
| TWI316942B (en) | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents | |
| JP6359563B2 (ja) | ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 | |
| CN115244056A (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| JP7651694B2 (ja) | 化合物、前記化合物の互変異性体、前記化合物の立体異性体、前記化合物の水和物、前記化合物の溶媒和物または前記化合物の薬学的に許容される塩、及び薬物組成物 | |
| JPWO2019217890A5 (https=) | ||
| JP7621289B2 (ja) | ベンゾジアゼピン系化合物及びその製造方法並びに医薬における作用 | |
| JPWO2022216971A5 (https=) | ||
| JPH03503529A (ja) | 白金（２）錯体、その製造法および抗腫瘍剤としての利用 | |
| IL274504B2 (en) | Acss2 inhibitors and methods of use thereof | |
| CA2633057A1 (fr) | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique | |
| JP2021514395A5 (https=) | ||
| JP2020111571A5 (https=) | ||
| JPH05503534A (ja) | （２Ｒ，３Ｒ）―シス―β―フエニルグリシド酸の製造方法 | |
| RU2013107759A (ru) | Производные оксадиазола и пиридазина, их получение и применение в терапии | |
| CA2513295A1 (en) | Oxazole derivatives as inhibitors of cyclooxygenase | |
| JP3840378B2 (ja) | インドール誘導体 | |
| AU2021328979A9 (en) | Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof | |
| CN108863925A (zh) | 一种氘代化合物、其盐、制备方法、药物组合物及用途 | |
| US9353061B2 (en) | 3,5,N-trihydroxy-alkanamide and derivatives: method for making same and use thereof | |
| JPWO2023028564A5 (https=) | ||
| JP2022549346A (ja) | マイコバクテリア感染症の処置のためのインドールカルボキサミド化合物およびその使用 |